학술논문
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
Document Type
Article
Author
Feagan, B.G.; Sands, B.E.; Sandborn, W.J.; Germinaro, M.; Vetter, M.; Shao, J.; Sheng, S.; Johanns, J.; Panés, J.; Tkachev, A.; Kalimullina, D.; Petryka, R.; Osipenko, M.; Tsarynna, N.; Bilianskyi, L.; Kleczkowski, D.; Yurkiv, A.; Woynarowski, M.; Abrahamovych, O.; Ivanishyn, O.; Rydzewska, G.; Kierkus, J.; Petrova, E.; Vasilevskaya, O.; Afanasieva, H.; Francesconi, C.; Leszczyszyn, J.; Bunkova, E.; Platonov, D.; Datsenko, O.; Gridnyev, O.; Hospodarsky, I.; Prystupa, L.; Stanislavchuk, M.; Pershko, A.; Shchukina, O.; Simanenkov, V.; Golovchenko, O.; Holderman, W.; Lasa, J.; Begun, J.; de Lourdes de Abreu Ferrari, M.; Lopez, P.; Obrezan, A.; Farooq, S.; Tiongco, F.; Novillo, A.; Tron, E.; Macrae, F.; Leong, R.; Yukie Sassaki, L.; Zaltman, C.; Kaiser Junior, R.; Stallmach, A.; Klaus, J.; Martinez, M.; Ruiz, A.; Abdulkhakov, R.; Sharma, V.; Korman, L.; Lord, J.; Patel, B.; Ritter, T.
Source
In: The Lancet Gastroenterology and Hepatology . (The Lancet Gastroenterology and Hepatology, April 2023, 8(4):307-320)
Subject
Language
English
ISSN
24681253